Report overview
HER2 (human epidermal growth factor receptor 2) is a protein that appears on the surface of some breast cancer cells. It may also be called HER2/neu or ErbB2.HER2-negative breast cancer means that the people have little or no HER2 protein.
This report contains market size and forecasts of HER2-negative Breast Cancer Treatment in Global, including the following market information:
Global HER2-negative Breast Cancer Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global HER2-negative Breast Cancer Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Chemotherapy Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of HER2-negative Breast Cancer Treatment include AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Pfizer, Novartis, Pfizer, GlaxoSmithKline, Novartis and Merck and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the HER2-negative Breast Cancer Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global HER2-negative Breast Cancer Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global HER2-negative Breast Cancer Treatment Market Segment Percentages, by Type, 2021 (%)
Chemotherapy
Surgery
Radiation
Hormonal therapy/endocrine therapy
Global HER2-negative Breast Cancer Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global HER2-negative Breast Cancer Treatment Market Segment Percentages, by Application, 2021 (%)
Hosptial
Clinic
Global HER2-negative Breast Cancer Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global HER2-negative Breast Cancer Treatment Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies HER2-negative Breast Cancer Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies HER2-negative Breast Cancer Treatment revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
AstraZeneca
Bristol-Myers Squibb
Eli Lilly
Pfizer
Novartis
Pfizer
GlaxoSmithKline
Novartis
Merck
Eli Lilly
